Syndicated sales analysis firms IRi and SPINS partner on new natural/organic food segmentation
CHICAGO — Information Resources Inc. and SPINS on Wednesday announced the integration of SPINS’ natural/organic food segmentation and industry expertise with IRi’s Consumer Network household panel. The coupling is expected to create a natural/organic segmentation capability that empowers CPG manufacturers and retailers to more effectively identify and market to consumers and shoppers in the fast growing natural/organic sector.
"Our relationship with SPINS significantly expands IRi’s coverage within the natural/organic products industry and overall health and wellness sector,” stated Robert Tomei, president of Consumer & Shopper Marketing, IRi. “It also enables us to collaborate with recognized domain experts to best understand business implications and offer the optimal natural and organic-based information and consumer and shopper-based segmentation solutions to our clients.”
"The natural products market topped $80 billion in 2012. In the past year, nearly every household in the U.S. purchased natural products and more than two-thirds of households are buying organic products," stated Tony Olson, CEO SPINS. "The natural products industry continues to experience double-digit growth year over year, and to sustain this growth, the market needs complete solutions. We are thrilled to partner with IRi to provide manufacturer and retailer clients with advanced insights into the natural consumer so they can continue to respond to the growing demand and propel the industry forward.”
The IRi Consumer Network panel leverages in-home scanner-based purchase reporting and proprietary analytical solutions to assist manufacturers and retailers in assessing volume and share level trends based upon what is happening in the home: who is buying, where, how often, the level of brand and retailer loyalty, and the impact of consumer and shopper promotions.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.
Walgreens, NONPF partner in nurse practitioner education
WASHINGTON — Walgreens Take Care Health Systems and the National Organization of Nurse Practitioner Faculties are sponsoring a new program to support the clinical education of nurse practitioners, the two announced.
"NONPF is very pleased to have the support of a strong clinical leader such as Take Care Health Systems," president Debra Barksdale said. "The important role that NPs play by providing care at Take Care Clinics and the clinical education of NP students makes this a natural partnership."
The program will include a Preceptor Web Portal containing web-based resources that clinical preceptors — instructors who play an important role in the education of nurse practitioners — use to promote education for NPs nationwide. NONPF and Take Care said additional resources and orientation materials were necessary to help preceptors enhance their abilities to teach students in the clinical setting. The web portal is expected to become available this summer.
"Take Care Health Systems recognizes the valuable role NPs can play toward helping increase access to care for patients and addressing the gaps in care facing the U.S. healthcare system today," Take Care chief nurse practitioner officer and clinical advocate Sandra Ryan said. "We are committed to having a significant leadership role in supporting education of NPs and look forward to bringing together our experience with the resources of NONPF to support preceptors and NP clinical education at the national level."
FDA approves J&J’s Simponi for ulcerative colitis
SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating ulcerative colitis, the agency said Wednesday.
The FDA announced the approval of Simponi (golimumab) for adults with moderate to severe forms of the condition, a chronic disease that affects more than 600,000 Americans. The disease causes inflammation and ulcers in the inner lining of the large intestine and can lead to abdominal discomfort, gastrointestinal bleeding, pus and diarrhea. The drug — part of a class known as tumor necrosis factor inhibitors, so named because they work by suppressing TNF, a major reason in causing inflammatory and autoimmune disorders — is made by J&J subsidiary Janssen Ortho Biotech, based in Horsham, Pa.
The drug is already approved to treat rheumatoid arthritis.